2026-527184-15-00Not yet recruitingPhase 1
An open-label phase 1 dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and exploratory assessments of PACAB-002 in patients with ovarian cancer with peritoneal spread
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 4 Aug 2026
- Start date
- 1 Jan 2027
- Lead sponsor
- Nadeno Nanoscience AS
- Diseases
- Ovarian cancer
- EU CT number
- 2026-527184-15-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 21
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with ovarian cancer that has spread within the abdomen (peritoneal spread). It tests the safety of PACAB-002 at rising doses.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Ovarian cancer with peritoneal spread
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.